Our scientists’ deep understanding of cellular models and expertise in the pathology of fibrosis has led to the development of a robust and predictive in vitro model organ-specific fibrosis using confocal microscopy in either a 2D or 3D cell culture format. Our models are used to support compound profiling across a diverse range of client projects for which organ-specific fibrosis presents as a disease pathology.
Sygnature’s fibrosis model can be used to profile your potential anti-fibrotic agents in a high-throughput manner by following biomarker expression. Our model enables the study of fibrosis-related parameters in response to drug treatment such as stellate cell activation, extracellular matrix deposition, changes in pro-fibrotic mRNA expression and specific fibrotic signalling events (e.g. TGF-β/Smad3, and TGF-β receptor dimerization).
Our models can be used to investigate compound Mechanism of Action and to support integrated Hit Identification and Lead Optimisation drug discovery cascades, with our scientific team providing intellectual input into project screening strategies and progression pathways and meaningful data interpretation.
Sygnature Discovery offers of a high content imaging rat kidney fibrosis model for high throughput screening of anti-fibrotic compounds. We are currently validating the lung and liver models.